XSTO
2CUREX
Market cap1mUSD
Aug 31, Last price
0.42SEK
Name
2cureX AB
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
20.00%
Shrs. gr., 5y
13.03%
Rev. gr., 5y
-54.18%
Revenues
0
Net income
-3m
L-36.77%
CFO
-5m
L-85.18%
Dividend
Jun 27, 20250.084 SEK/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Copenhagen, Denmark, 2cureX AB (publ) is a European medtech firm established in 2006. The company's core offering is IndiTreat, an in-vitro diagnostic test designed to forecast how cancer patients will respond to or resist various drug treatments, thereby guiding clinicians in selecting the most effective therapy. Additionally, 2cureX is actively advancing IndiTreat through clinical programs targeting a range of cancers, including breast, colorectal, ovarian, and pancreatic types.
Key people
Povl-Andre Bendz
Independent Chairman of the Board · since 2017
Grith Hagel
Head of Project Management
Henrik Harling
Chief Medical Officer · since 2019
Maarten van der Linden
Chief Business Officer · since 2017
Camilla Huse Bondesson
Director · since 2019
Ole Thastrup
Chief Executive Officer, Director
Timm-H. Jessen
Independent Director · since 2006
Headquarters & legal address
Box 159
Landskrona 261 22
SE
Landskrona 261 22
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||